Literature DB >> 22339044

How much does intellectual disability really cost? First estimates for Australia.

Christopher M Doran1, Stewart L Einfeld, Rosamond H Madden, Michael Otim, Siân K Horstead, Louise A Ellis, Eric Emerson.   

Abstract

BACKGROUND: Given the paucity of relevant data, this study estimates the cost of intellectual disability (ID) to families and the government in Australia.
METHOD: Family costs were collected via the Client Service Receipt Inventory, recording information relating to service use and personal expense as a consequence of ID. Government expenditure on the provision of support and services was estimated using top-down costing.
RESULTS: A total of 109 parents participated. The cost of ID in Australia is high, especially for families. Total economic costs of ID are close to $14,720 billion annually. Opportunity cost of lost time provided 85% of family expense. A comparison of family expense and social welfare benefits received suggests that families suffer considerable loss. This may impact on families' physical and emotional wellbeing.
CONCLUSIONS: Monitoring of changes in expenditure is required. Policies should ensure that money devoted to ID is allocated in a rational, equitable, and cost-effective manner.

Mesh:

Year:  2012        PMID: 22339044     DOI: 10.3109/13668250.2011.648609

Source DB:  PubMed          Journal:  J Intellect Dev Disabil        ISSN: 1366-8250


  14 in total

1.  Using Discrete-Choice Experiment Methods to Estimate the Value of Informal Care: The Case of Children with Intellectual Disability.

Authors:  Sheena Arora; Stephen Goodall; Rosalie Viney; Stewart Einfeld
Journal:  Pharmacoeconomics       Date:  2019-04       Impact factor: 4.981

2.  Reduced cognition in Syngap1 mutants is caused by isolated damage within developing forebrain excitatory neurons.

Authors:  Emin D Ozkan; Thomas K Creson; Enikö A Kramár; Camilo Rojas; Ron R Seese; Alex H Babyan; Yulin Shi; Rocco Lucero; Xiangmin Xu; Jeffrey L Noebels; Courtney A Miller; Gary Lynch; Gavin Rumbaugh
Journal:  Neuron       Date:  2014-06-18       Impact factor: 17.173

3.  Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe.

Authors:  Karine Chevreul; Coralie Gandré; Karen Berg Brigham; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; László Gulácsi; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Ulf Persson; Giovani Fattore
Journal:  Eur J Health Econ       Date:  2016-04-12

4.  Cost-Utility Analysis of Prophylactic Dextrose Gel vs Standard Care for Neonatal Hypoglycemia in At-Risk Infants.

Authors:  Matthew J Glasgow; Richard Edlin; Jane E Harding
Journal:  J Pediatr       Date:  2020-07-04       Impact factor: 4.406

5.  The respiratory health of urban indigenous children aged less than 5 years: study protocol for a prospective cohort study.

Authors:  Kerry K Hall; Anne B Chang; Theo P Sloots; Jennie Anderson; Anita Kemp; Jan Hammill; Michael Otim; Kerry-Ann F O'Grady
Journal:  BMC Pediatr       Date:  2015-05-14       Impact factor: 2.125

Review 6.  Physical activity levels in adults with intellectual disabilities: A systematic review.

Authors:  Yetunde Marion Dairo; Johnny Collett; Helen Dawes; G Reza Oskrochi
Journal:  Prev Med Rep       Date:  2016-06-08

7.  Cost burden and net monetary benefit loss of neonatal hypoglycaemia.

Authors:  Matthew J Glasgow; Richard Edlin; Jane E Harding
Journal:  BMC Health Serv Res       Date:  2021-02-05       Impact factor: 2.655

8.  Gestational age at birth and risk of intellectual disability without a common genetic cause.

Authors:  Hein Heuvelman; Kathryn Abel; Susanne Wicks; Renee Gardner; Edward Johnstone; Brian Lee; Cecilia Magnusson; Christina Dalman; Dheeraj Rai
Journal:  Eur J Epidemiol       Date:  2017-12-06       Impact factor: 8.082

9.  Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial.

Authors:  Daryl Efron; Kaitlyn Taylor; Jonathan M Payne; Jeremy L Freeman; Noel Cranswick; Melissa Mulraney; Chidambaram Prakash; Katherine J Lee; Katrina Williams
Journal:  BMJ Open       Date:  2020-03-08       Impact factor: 2.692

10.  Abnormally Methylated FMR1 in Absence of a Detectable Full Mutation in a U.S.A Patient Cohort Referred for Fragile X Testing.

Authors:  Charles H Hensel; Rena J Vanzo; Megan M Martin; Ling Ling; Solange M Aliaga; Minh Bui; David I Francis; Hope Twede; Michael H Field; Jonathon W Morison; David J Amor; David E Godler
Journal:  Sci Rep       Date:  2019-10-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.